VenatoRx Pharmaceuticals, Inc.
Venatorx Pharmaceuticals is a private company dedicated to discovering and developing novel anti-infectives to combat multi-drug-resistant bacterial and hard-to-treat viral infections. Founded in 2010, it has established a world-class R&D organization and is advancing multiple programs, including cefepime-taniborbactam, a Phase 3 investigational antibiotic for complicated urinary tract infections, supported by significant collaborations and funding from various health agencies and partners. The company is actively engaged in research and development of broad-spectrum β-lactamase inhibitors, such as taniborbactam, which exhibits activity against serine- and metallo-β-lactamases, including NDM, VIM, KPC, and OXA-48, and is in clinical development for treating infections caused by carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa. Venatorx's pipeline includes products like cefepime-taniborbactam, ceftibuten-ledaborbactam, and VNRX-9945, with ongoing clinical trials and extensive scientific publications demonstrating its commitment to addressing antimicrobial resistance.
Industries
Nr. of Employees
medium (51-250)
VenatoRx Pharmaceuticals, Inc.
Malvern, Pennsylvania, United States, North America
Products
Intravenous cephalosporin combined with a bicyclic boronate β‑lactamase inhibitor (clinical‑stage)
An intravenous cephalosporin paired with a broad‑spectrum bicyclic boronate β‑lactamase inhibitor in clinical development to restore β‑lactam activity against serine and metallo‑β‑lactamase producing Gram‑negative pathogens.
Oral cephalosporin combined with an orally bioavailable boronate inhibitor prodrug (development‑stage)
An oral cephalosporin paired with an orally bioavailable boronate inhibitor prodrug designed to restore oral cephalosporin activity against resistant Enterobacterales for outpatient therapy.
Discovery‑stage non‑β‑lactam penicillin‑binding protein inhibitor program
Early‑stage discovery program targeting penicillin‑binding proteins using non‑β‑lactam chemotypes to address bacterial resistance mechanisms.
Discovery‑stage antiviral candidate (hepatitis B)
Antiviral discovery program to identify therapeutic candidates for chronic hepatitis B virus infection.
Intravenous cephalosporin combined with a bicyclic boronate β‑lactamase inhibitor (clinical‑stage)
An intravenous cephalosporin paired with a broad‑spectrum bicyclic boronate β‑lactamase inhibitor in clinical development to restore β‑lactam activity against serine and metallo‑β‑lactamase producing Gram‑negative pathogens.
Oral cephalosporin combined with an orally bioavailable boronate inhibitor prodrug (development‑stage)
An oral cephalosporin paired with an orally bioavailable boronate inhibitor prodrug designed to restore oral cephalosporin activity against resistant Enterobacterales for outpatient therapy.
Discovery‑stage non‑β‑lactam penicillin‑binding protein inhibitor program
Early‑stage discovery program targeting penicillin‑binding proteins using non‑β‑lactam chemotypes to address bacterial resistance mechanisms.
Discovery‑stage antiviral candidate (hepatitis B)
Antiviral discovery program to identify therapeutic candidates for chronic hepatitis B virus infection.
Services
Collaborative development and licensing
Execution of licensing agreements, territorial commercialization arrangements, and distribution partnerships with industry and global health organizations.
Government contract and program execution
Program management and delivery under government‑funded development and procurement contracts for anti‑infective candidates and preparedness programs.
Clinical development and trial execution support
Design and operational execution of clinical trials for complicated infections, including Phase 3 trial management and clinical pharmacokinetic assessments.
Collaborative development and licensing
Execution of licensing agreements, territorial commercialization arrangements, and distribution partnerships with industry and global health organizations.
Government contract and program execution
Program management and delivery under government‑funded development and procurement contracts for anti‑infective candidates and preparedness programs.
Clinical development and trial execution support
Design and operational execution of clinical trials for complicated infections, including Phase 3 trial management and clinical pharmacokinetic assessments.
Expertise Areas
- Antibacterial small‑molecule discovery
- Oral prodrug and bioavailability strategies
- Broad‑spectrum β‑lactamase inhibitor development
- Preclinical and translational PK/PD and exposure‑response analysis
Key Technologies
- Bicyclic boronate β‑lactamase inhibitor chemistry
- Oral prodrug design for small molecules
- β‑lactam/β‑lactamase‑inhibitor combination therapy
- CLSI/ISO broth microdilution MIC testing